tbuckley/cabot-search huggingface dataset:
Ulk1/Rab9-mediated alternative mitophagy confers cardioprotection during energy stress
Authors: Rimpy Dhingra, Inna Rabinovich-Nikitin, Lorrie A. Kirshenbaum
Journal: Journal of Clinical Investigation (2019)

The heart relies on mitochondria-derived energy production for continuous contraction and relaxation; therefore, the maintenance of a pool of healthy mitochondria is essential for sustaining normal cardiac performance. Mitophagy serves as a critical process for maintaining mitochondrial quality control and involves the PTEN-induced kinase 1/Parkin (Pink1/Parkin) pathway and autophagosomes labeled with the autophagy proteins autophagy-related 7 (ATG) and light chain 3 (LC3). In this issue of the JCI, Saito and colleagues identify an alternative pathway for mitophagy that utilizes the serine/threonine protein kinase Unc-51-like kinase 1 (Ulk1) and the small GTPase Rab9 to clear damaged mitochondria independently of conventional autophagy proteins. Together, the results of this study reveal that Ulk1 phosphorylation of Rab9 at serine 179 is critical for alternative mitophagy and cardioprotection under energy stress conditions.
p300 Mediates Muscle Wasting in Lewis Lung Carcinoma
Authors: Thomas K. Sin, James Z. Zhu, Guohua Zhang, Yi-Ping Li
Journal: Cancer Research (2019)

C/EBPβ is a key mediator of cancer-induced skeletal muscle wasting. However, the signaling mechanisms that activate C/EBPβ in the cancer milieu are poorly defined. Here, we report cancer-induced muscle wasting requires the transcriptional cofactor p300, which is critical for the activation of C/EBPβ. Conditioned media from diverse types of tumor cells as well as recombinant HSP70 and HSP90 provoked rapid acetylation of C/EBPβ in myotubes, particularly at its Lys39 residue. Overexpression of C/EBPβ with mutated Lys39 impaired Lewis lung carcinoma (LLC)-induced activation of the C/EBPβ-dependent catabolic response, which included upregulation of E3 ligases UBR2 and atrogin1/MAFbx, increased LC3-II, and loss of muscle proteins both in myotubes and mouse muscle. Silencing p300 in myotubes or overexpressing a dominant negative p300 mutant lacking acetyltransferase activity in mouse muscle attenuated LLC tumor-induced muscle catabolism. Administration of pharmacologic p300 inhibitor C646, but not PCAF/GCN5 inhibitor CPTH6, spared LLC tumor-bearing mice from muscle wasting. Furthermore, mice with muscle-specific p300 knockout were resistant to LLC tumor-induced muscle wasting. These data suggest that p300 is a key mediator of LLC tumor-induced muscle wasting whose acetyltransferase activity may be targeted for therapeutic benefit in this disease. SIGNIFICANCE: These findings demonstrate that tumor-induced muscle wasting in mice is abrogated by knockout, mutation of Lys39 or Asp1399, and pharmacologic inhibition of p300.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/7/1331/F1.large.jpg.
Ongoing GP shortage puts NHS long term plan at risk, warn experts
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Chronic shortages of staff in critical areas such as general practice are jeopardising the NHS’s long term plan to strengthen primary and community care in England, experts have warned.1

New research by the charity the Health Foundation found “ongoing deterioration” in workforce numbers in primary and community care, nursing, and mental health services, with staff numbers failing to keep pace with demand.

Shifting care out of hospitals and closer to people’s homes was identified as a major priority in the NHS Long Term Plan , published in January.2

But Anita Charlesworth, director of research and economics at the Health Foundation and one of the report’s coauthors, said, “If [the NHS] can’t recruit and retain …
Abstract 19386: The Mitochondrial Deacetylase Sirtuin 3 (sirt3) is Important in the Pathogenesis of Both Pulmonary Hypertension and Pulmonary Fibrosis: Potential for an “Overlap Syndrome” and a Common Therapy?
Authors: Roxane Paulin, Hengjia Zang, Aristeidis Boukouris, Vikram Gurtu, Alois Haromy, Evangelos D Michelakis
Journal: Circulation (2015)

Introduction: Pulmonary arterial hypertension (PAH) is often associated with interstitial lung disease, like idiopathic pulmonary fibrosis (IPF). IPF pulmonary fibroblasts have a very similar pro-proliferative and anti-apoptotic phenotype similar to PAH vascular smooth muscle cells (SMC). As this phenotype is often associated with a cancer-like mitochondrial suppression, we hypothesized that a common mitochondria abnormality may underlie both PAH and IPF. We speculated that the loss of the mitochondrial deacetylase Sirt3, which we recently showed promotes PAH, will also promote IPF. Results: SIRT3 expression was decreased in human IPF-PH lungs (transplant recipients, n=7) and in Sirt3 wild type (Sirt3WT)+ bleomycin BLEO lungs (n=15 for each) and fibroblasts compared to healthy lungs (unused transplant tissue, n=3) and Sirt3WT. Sirt3 knockout (Sirt3KO) fibroblasts, like Sirt3WT+BLEO, had decreased mitochondrial function assessed by decreased pyruvate dehydrogenase activity, decreased respiration (Seahorse Assay) and increased mitochondrial membrane potential (TMRM dye in live cell imaging). Sirt3KO and Sirt3WT+BLEO fibroblasts had increased collagen production and smooth muscle actin expression (immunoblot). All of these findings are very similar to those in pulmonary artery SMCs from the same Sirt3KO animals, which develop spontaneous PAH. In vivo, Sirt3KO mice treated with BLEO developed worse IPF than Sirt3WT+BLEO (dynamic resistance 2±0.5 vs 1.4±0.2cmH2O.s/mL, dynamic elastance 20±3 vs 38±10cmH2O/mL). Intra-tracheal delivery of an adenovirus overexpressing SIRT3 improved both Sirt3KO+BLEO and Sirt3WT+BLEO compared to GFP-only adenovirus. We have previously showed that the same virus reverses PAH in rodents. Conclusion: Sirt3 downregulation plays an important role in the development of IPF. While the exact mechanisms by which Sirt3 is downregulated remains to be established, this work opens new perspectives for the treatment of IPF. Given the frequent overlap of IPF and pulmonary hypertension in the same patients, our data suggest the intriguing possibility that they both represent aspects of an “overlap syndrome”, which may benefit from similar therapeutic approaches, despite the differences in the “cell of origin”.
Abstract 11404: Impact of Infection-Related Hospital Admissions With Heart Failure on Clinical Outcomes: Insights From the Gulf CARE Study
Authors: Amar M Salam, Kadhim Sulaiman, Jassim Al-Suwaidi, Khalid AlHabib, Wael Almahmeed, Alawi Alsheikh-Ali, Ahmed Al-Motarreb, Prashanth Panduranga, Husam AlFaleh, Abdelfatah Elasfar, Nooshin Bazargani, Mustafa Ridha, Bassam Bulbanat, Mohammed Al-Jarallah, Haitham Amin, Nidal Asaad, Rajvir Singh, Magdi Yacoub
Journal: Circulation (2014)

OBJECTIVES: Although community acquired infections (CAI) are one of the most common causes for hospitalization of patients with heart failure (HF), yet very few studies have systematically examined...
The art of clozapine therapy and “clozaphobia”
Authors: James Paul Pandarakalam
Journal: BMJ (2019)

The BMJ ’s article on clozapine deaths1 seems to increase “clozaphobia”—the fear of prescribing clozapine,2 which is potentially a transformative drug for people with schizophrenia. Since 1975, many clinicians have had reservations about its use because of the rare incidence of agranulocytosis and the unfortunate initial fatalities in Finland. The risk of developing granulocytopenia and agranulocytosis while taking clozapine is around 1.0%.3 It happens mostly in …
Louie Mary Mangar
Authors: Will Mangar
Journal: BMJ (2019)

Louie Mary Mangar was born in Norwich, the only child and daughter of a headmistress and shoe business owner. she had a happy—albeit lonely—childhood, excelled academically at school, and in 1955 joined a mere handful of other female students for the first year of medicine at Sheffield University. Having married her first husband, Subei Adamo, in 1957, Louie gave birth to her first son, Richard, and combined family life with the highly successful completion of her medical school studies. This was a unique achievement in a British medical school in the mid-1950s. …
Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial
Authors: Liv Guro Engen Hanem, Øyvind Salvesen, Petur B Juliusson, Sven M Carlsen, Marit Cecilie Fonn Nossum, Marte Øye Vaage, Rønnaug Ødegård, Eszter Vanky
Journal: The Lancet Child & Adolescent Health (2019)
Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis
Authors: Wen-Chi Chen, I-Fang Hsin, Ping-Hsien Chen, Ping-I Hsu, Yen-Po Wang, Jin-Shiung Cheng, Huey-Shyan Lin, Ming-Chih Hou, Fa-Yauh Lee
Journal: Clinical Gastroenterology and Hepatology (2019)
Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infections—Reply
Authors: Patrick N. A. Harris, Paul Tambyah, David L. Paterson
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
18F-FDG-Labeled Autologous Leukocyte PET-CT in a Patient With Aortic Valve-Tube Graft Infection After Bentall Procedure
Authors: Apurva Sood, Anish Bhattacharya, Pankaj Aggarwal, Rajender Kumar Basher, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2019)

Infection of aortic valve-tube graft, although rare, is associated with high morbidity and mortality. Early identification of site and extent of infection is not only challenging but also crucial for adequate patient management and prognostication of disease. Combined clinical, laboratory investigation and imaging modalities assist in the identification of aortic valve graft infection. Molecular imaging techniques like PET/CT using F-FDG and F-FDG-labeled autologous leukocytes (LALs) have improved the sensitivity for detection of infection, resulting in better outcome for these patients. F-FDG-labeled autologous leukocyte PET/CT in our patient after Bentall procedure accurately localized the site and extent of infection.
Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).
Authors: Marcus Smith Noel, Martin Fernandez-Zapico, Gerald H. Sokol, Giuseppe Del Priore
Journal: Journal of Clinical Oncology (2019)

277 Background: SM88 is an oral tyrosine isomer ( TI) and repurposed drugs (CYP3a4 inducer, mTOR inhibitor, oxidative stress catalyst). This regimen has reported no drug related grade 3, 4 or 5 adverse events (JCO 2013 31: e22095) and potential clinical activity in PC (JCO 2018 36: TPS 4156). PC patients have risk factors for malabsorption and a cachexia syndrome rendering some oral therapies potential unreliable. We present PK data from the completely enrolled first stage of an ongoing dose finding phase II in PC. Methods: Open label randomized TI (control – 230 mg bid vs. experimental - 430 mg bid) along with the lowest approved doses of the other agents. Samples were drawn from four patients at pre-dose and up to six h post dosing on cycle day one for two cycles after a single dose of all four components. Results: Mean age: 71.3 (59 – 80), BMI = 25.3 (21.9 – 28.8) and median three prior chemo lines, two post-pancreas surgery and one s/p RT. There was no evidence that the combination altered the expected PKs at C2. There were no serious drug related adverse events. Favorable RECIST, PERCIST or biomarker activity was documented at both TI dose levels. The PK results of the repurposed drugs were consistent with the published data for these agents, despite the combination use and lower than typical label doses; data will be provided. These results were consistent with previous animal and healthier patient PK of SM88. Conclusions: Single dose C1 and C2 TI PKs are consistent with preclinical predictions (ESMO 2016. Ann Oncol (2016) 27 (supp_6): 1605P) and those previously reported in a healthier population of cancer patients (JCO 2018 36: TPS 4156). Based on these results and PK ones from the repurposed drugs, additional data is being collected in order to define the ongoing phase II expansion cohort dose. SM-88 appears to have predictable PK even in heavily pretreated PC patient with prior radiotherapy and surgery. Clinical trial information: NCT03512756. [Table: see text]
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
Authors: Shereen Oon, Molla Huq, Vera Golder, Pei Xuan Ong, Eric F Morand, Mandana Nikpour
Journal: Annals of the Rheumatic Diseases (2019)

We evaluated the discriminant capacity of the Lupus Low Disease Activity State (LLDAS) in post-hoc analysis of data from the BLISS-52 and BLISS-76 trials of belimumab in systemic lupus erythematosus (SLE).LLDAS attainment, discrimination between belimumab and placebo arms, and the effects in subgroups with high disease activity at recruitment were evaluated at week 52 using appropriate descriptive statistics, χ2 test and logistic regression.At week 52, for belimumab 10 mg/kg, 17.0% and 19.3% of patients who achieved a Systemic Lupus Erythematosus Responder Index-4 also attained LLDAS in BLISS-52 and BLISS-76, respectively. Significantly more patients attained LLDAS on belimumab 10 mg/kg compared with placebo (12.5% vs 5.8%, OR 2.32, p=0.02 for BLISS-52; 14.4% vs 7.8%, OR 1.98, p=0.04 for BLISS-76). In a subgroup analysis, the difference in week 52 LLDAS attainment between belimumab 10 mg/kg and placebo was greater in patients who had higher disease activity at baseline, compared with the overall group.LLDAS was able to discriminate belimumab 10 mg/kg from placebo in the BLISS-52 and BLISS-76 trials. Our findings support the validity of LLDAS as an outcome measure in SLE clinical trials.
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors
Authors: Patrick Robelin, Julien Hadoux, Julien Forestier, David Planchard, Valérie Hervieu, Amandine Berdelou, Jean-Yves Scoazec, Pierre-Jean Valette, Sophie Leboulleux, Michel Ducreux, Catherine Lombard-Bohas, Eric Baudin, Thomas Walter
Journal: Journal of Thoracic Oncology (2019)
A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates
Authors: Shamina M. Rangwala, Katharine D’Aquino, Yue-Mei Zhang, Lindsay Bader, Wilson Edwards, Songmao Zheng, Annette Eckardt, Ann Lacombe, Rebecca Pick, Veronica Moreno, Lijuan Kang, Wenying Jian, Eric Arnoult, Martin Case, Celia Jenkinson, Ellen Chi, Ronald V. Swanson, Paul Kievit, Kevin Grove, Mark Macielag, Mark D. Erion, Ranabir SinhaRoy, James N. Leonard
Journal: Cell Metabolism (2019)
Recombinant Human Thrombopoietin (rhTPO) and High-Dose Dexamethasone (HD-DXM) Versus High-Dose Dexamethasone Monotherapy As Frontline Treatment in Newly Diagnosed Adult Immune Thrombocytopenia (ITP): a Prospective, Multicentre, Randomised, Controlled Trial
Authors: Miaomiao Wang, Ping Qin, Hai Zhou, Fang Zhou, Hongguo Zhao, Xin Wang, Ruirong Xu, Daqi Li, Lei Wang, Yuhong Zhou, Ying Feng, Mei Zhang, Lan Yang, Xiaomin Wang, Qingshu Zeng, Haiyan Zhang, Zhaogang Sun, Jingxia Wang, Guoqiang Liu, Xinhong Guo, Zhencheng Wang, Wenzheng Yu, Xiaoxia Chu, Chenglu Yuan, Kehong Bi, Yili Wang, Xuehong Ran, Jun Peng, Ming Hou
Journal: Blood (2017)
Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen
Authors: Mathias J Rummel, Ann Janssens, David MacDonald, Mary-Margaret Keating, Jan Zaucha, Jaclyn Davis, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg
Journal: Blood (2018)
Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL)
Authors: Angela Dispenzieri, Surendra Dasari, Bonnie Kaye Arendt, Mindy Kohlhagen Kohlhagen, Taxiarchis Kourelis, Morie A. Gertz, Shaji K. Kumar, S. Vincent Rajkumar, Francis K. Buadi, David Dingli, Nelson Leung, Prashant Kapoor, Ronald S. Go, Robert A. Kyle, Eli Muchtar, Yi Hwa, Rahma Warsame, Wilson I Gonsalves, Steven Zeldenrust, Amie Fonder, Miriam Hobbs, John A. Lust, Stephen J. Russell, David L. Murray
Journal: Blood (2018)
Abstract P057: Cardiovascular Diseases and Cancer Incidences Associated With Cardiovascular Risk Profile: Results from MATISS Italian Cohort
Authors: Smona C Ursu, Luigi Palmieri, Simona Giampaoli, Fabio Pannozzo, Cinzia Lo Noce, Annarita Vestri, Jeremiah Stamler
Journal: Circulation (2015)

Background: Individuals with low levels of cardiovascular risk factors experience low incidence of subsequent cardiovascular diseases (CVD). The aims of this study were to assess cancer incidence in people with favorable (low) CVD risk profile and its association with educational level (EL). Methods: The MATISS longitudinal cohort comprised 3609 men and 4146 women aged 20-70 years, free of CVD and cancer at baseline with validated non-fatal and fatal CVD and cancer events during a median 17.7 years of follow-up. People at baseline were classified as ‘low risk’ with total cholesterol &lt;240 mg/dl and blood pressure &lt;140/90 mmHg and BMI &lt;30.0 kg/m 2 and no hypertension treatment and no diabetes and no smoking habit and ‘high risk’ (total cholesterol &gt;=240mg/dl or blood pressure &gt;=140/90 mmHg or BMI &gt;=30.0 kg/m 2 or hypertension treatment, diabetes, smoking). EL was classified as low (LEL=elementary school) and middle-high (MHEL=middle/high school/university). Results: 724 cancer and 571 CVD events occurred; 22.7% of participants were ‘low risk’; 77.3% were ‘high risk; 61.5% had LEL. Cancer and CVD incidences increased with age; age-adjusted cancer and CVD incidence were higher in men compared to women (cancer: 68.92 versus 48.95 x 10,000 person-years; CVD: 64.18 versus 29.5 x 10,000 person-years). Incidences of cancer and CVD were higher in LEL (cancer: 83.22 versus 50.35 x 10,000 person-years in men and 51.67 versus 33.59 x 10,000 person-years in women; CVD: 70.07 versus 64.84 x 10,000 person-years in men and 30.72 versus 17.89 x 10,000 person-years in women). Persons with ‘low risk’ profile experienced less cancers and CVD than persons with ‘high risk (cancer: 37.66 versus 72.3 x 10,000 person-years in men and 39.57 versus 50.07 x 10,000 person-years in women; CVD: 18.49 versus 69.75 per 10,000 person-years in men and 20.34 versus 30.7 x 10,000 person-years in women). In analysis by risk profile and EL considered together for both genders rates of both CVD and cancer were highest in those with less education classified as high risk (cancer: 85.2 versus 56.13 x 10,000 person-years in men and 50.97 versus 35.12 x 10,000 person-years in women; CVD: 74.58 versus 69.06 per 10,000 person-years in men and 30.87 versus 22.69 x 10,000 person-years in women). Conclusions: Increasing educational levels and prevalence of low CVD risk profile in the general population may be effective strategies for population-wide CVD and cancer prevention.
Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy
Authors: Kevin B. Einkauf, Guinevere Q. Lee, Ce Gao, Radwa Sharaf, Xiaoming Sun, Stephane Hua, Samantha M.Y. Chen, Chenyang Jiang, Xiaodong Lian, Fatema Z. Chowdhury, Eric S. Rosenberg, Tae-Wook Chun, Jonathan Z. Li, Xu G. Yu, Mathias Lichterfeld
Journal: Journal of Clinical Investigation (2019)

Chromosomal integration of genome-intact HIV-1 sequences into the host genome creates a reservoir of virally infected cells that persists throughout life, necessitating indefinite antiretroviral suppression therapy. During effective antiviral treatment, the majority of these proviruses remain transcriptionally silent, but mechanisms responsible for viral latency are insufficiently clear. Here, we used matched integration site and proviral sequencing (MIP-Seq), an experimental approach involving multiple displacement amplification of individual proviral species, followed by near-full-length HIV-1 next-generation sequencing and corresponding chromosomal integration site analysis to selectively map the chromosomal positions of intact and defective proviruses in 3 HIV-1-infected individuals undergoing long-term antiretroviral therapy. Simultaneously, chromatin accessibility and gene expression in autologous CD4+ T cells were analyzed by assays for transposase-accessible chromatin using sequencing (ATAC-Seq) and RNA-Seq. We observed that in comparison to proviruses with defective sequences, intact HIV-1 proviruses were enriched for non-genic chromosomal positions and more frequently showed an opposite orientation relative to host genes. In addition, intact HIV-1 proviruses were preferentially integrated in either relative proximity to or increased distance from active transcriptional start sites and to accessible chromatin regions. These studies strongly suggest selection of intact proviruses with features of deeper viral latency during prolonged antiretroviral therapy, and may be informative for targeting the genome-intact viral reservoir.
Abstract 20047: FXYD1 Protects Against Reactive Oxygen Species-Dependent Cardiac Remodelling and Fibrosis
Authors: Kristen J Bubb, Owen Tang, Thomas Hansen, Carmine Gentile, Gemma A Figtree
Journal: Circulation (2017)

Introduction: Fibrosis plays a critical role in cardiac pathophysiology. We have shown FXYD1 to be an endogenous protector of oxidative inhibition of the cardiac membrane Na+-K+ ATPase. However, the effects of FXYD1 on longer term cardiac signalling, and particularly cardiac fibrosis have not been examined. We hypothesized that absence of FXYD1 would worsen Angiotensin II-induced cardiac fibrosis. Methods and Results: In vivo studies were performed using wild-type (WT) and FXYD1 knockout (KO) mice. Under baseline conditions, cardiac perivascular fibrosis was ~3-fold higher in KO vs. WT mice (P<0.01), however interstitial fibrosis was absent. To stimulate cardiac interstitial fibrosis, Ang II (0.72 or 2.1 mg/kg/day) was infused via subcutaneous osmotic mini pump for 2 weeks. Ang II infusion resulted in elevated blood pressure (11 mmHg higher in FXYD1 KO mice vs. WT mice; P=0.01). This was associated with dose-dependent cardiac hypertrophy in FXYD1 KO mice (heart:body weight [mg/kg] sham: 4.8 +/- 0.3; AngII...
Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy
Authors: Matthew S. Davids, Andrew W. Roberts, William G. Wierda, Kathryn Humphrey, Debbie J Alter, Abdullah Masud, Eike C. Buss, Maria E. Verdugo, John F. Seymour
Journal: Blood (2018)